tirzepatide 2 mg Switch to in T2D More Effective Than Upping Dulaglutide Dose Tirzepatide (Mounjaro): Type 2 Diabetes

Taking a dose one day early disrupts the medication's pharmacokinetic profile, potentially reducing its weight management effectiveness and increasing side effect risk

This data demonstrates a significant reduction in emergency room visits, office visits, and overall healthcare resource utilization, which not only improves patient outcomes but also reduces the strain on healthcare systems

Subcutaneous injection of a compound with an unknown sterility profile carries real infection risk

The medicine may not be suitable for everybody

Jimena Hathaway, MD, MPH, indicates that the use of Wegovy increases the risk of a certain type of blindness and vision loss

Is one form more expensive than the other